Orchestra BioMed Holdings
OBIO on Nasdaq. Orchestra BioMed Holdings sells treatments for hypertension and artery disease to patients through Medtronic. Market value $571m.
Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-12.39 of spare cash in the past 12 months. A savings account pays about $4.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: 50 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$6.58 a share, 90% above its 1-year low
Over the past year the price has ranged from $3.46 to $7.82.
Pays no dividend
Prices from Friday’s close (20 November).
Five years of cash, in billions
| Revenue | |||||
| Revenue | n/a | $4m | $3m | $3m | $33m |
| Operating margin | |||||
| Operating margin | n/a | -924.3% | -1866.2% | -2437.5% | -154.7% |
| Debt to equity | |||||
| Debt to equity | n/a | n/a | n/a | 0.46 | 0.28 |
| Shares outstanding | |||||
| Shares outstanding | 0.01bn | 0.04bn | 0.04bn | 0.06bn | 0.08bn |
Health checks
- Free cash flow positive0 of 4 years
- Accounting checksSkipped: company is not yet profitable
- Debt0.28× equity
- Revenue growth, five yearsStrong, 111.6% a year
- Buying back its own sharesNo, 602% more shares since 2021
The quarter to September 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $91,000 last quarter, down 89% on a year ago.
- A loss of $19 million, compared with a loss of $21 million a year ago.
- It loses 195 cents on each $1 of sales, compared with 2670 cents a year earlier.
- Over the past 12 months it spent $64 million more cash than it brought in, compared with $61 million a year earlier.
- 24% more shares than a year ago. Each share owns a bit less of the company.
- Sales grew on a year ago in 1 of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| December 2024 | $253,000 |
| March 2025 | $868,000 |
| June 2025 | $836,000 |
| September 2025 | $861,000 |
| December 2025 | $31m |
| March 2026 | $110,000 |
| June 2026 | $88,000 |
| September 2026 | $91,000 |
| Quarter to | Amount |
|---|---|
| December 2024 | -$16m |
| March 2025 | -$19m |
| June 2025 | -$19m |
| September 2025 | -$21m |
| December 2025 | $6m |
| March 2026 | -$21m |
| June 2026 | -$24m |
| September 2026 | -$19m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 12 March 2026
- Next quarterly (estimated, 10-Q)
- 9 February 2027
Who owns it
None of the long-term investors we follow own it. 77 funds in all.
Largest holders overall
- RTW Investments, LP$41mAdded
- Perceptive Advisors$22m
- BlackRock$11mAdded
- Vanguard Capital Management$9mCut
- Geode Capital Management$4mAdded
- Alyeska Investment Group, L.P.$4m
- Propel Bio Management$4m
- UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS$3mNew
- State Street$2mAdded
- Rice Hall James & Associates$2mAdded
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
5 investors own more than 5%.
- Medtronic plcPassive investorat least 17.8%+2.4 pts(filed with 1 related holder)Since 31 December 2025
- RTW Investments, LPPassive investorat least 16.2%−3.0 pts(filed with 1 related holder)Since 9 November 2026
- RTW Master Fund, Ltd.Passive investorat least 9.6%−0.4 pts(filed with 1 related holder)Since 27 April 2026
- Perceptive Advisors LLCPassive investorat least 8.2%−1.8 pts(filed with 2 related holders)Since 30 September 2026
- Dana LorenzoPassive investorat least 5.5%(filed with 1 related holder)Since 15 November 2025
- BlackRock, Inc.Passive investorSold down below 5%Since 31 March 2025
| Holder | Stake | Since | |
|---|---|---|---|
Medtronic plc Passive investor | at least 17.8%+2.4 pts (filed with 1 related holder) | 31 December 2025 | |
RTW Investments, LP Passive investor | at least 16.2%−3.0 pts (filed with 1 related holder) | 9 November 2026 | |
RTW Master Fund, Ltd. Passive investor | at least 9.6%−0.4 pts (filed with 1 related holder) | 27 April 2026 | |
Perceptive Advisors LLC Passive investor | at least 8.2%−1.8 pts (filed with 2 related holders) | 30 September 2026 | |
Dana Lorenzo Passive investor | at least 5.5% (filed with 1 related holder) | 15 November 2025 | |
BlackRock, Inc. Passive investor | Sold down below 5% | 31 March 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 6 insiders bought $489,541 of shares on the open market. 1 sold $439,050, $439,050 of it under preset trading plans.
- Fain Eric SDirectorBought
- Date
- 9 November 2026
- Shares
- 20,000
- Price
- $5.00
- Value
- $100,000
- Pacitti DavidDirectorBought
- Date
- 9 November 2026
- Shares
- 20,000
- Price
- $5.00
- Value
- $100,000
- Hochman David PSee Remarks, DirectorBought
- Date
- 9 November 2026
- Shares
- 5,000
- Price
- $5.00
- Value
- $25,000
- Taylor Andrew LawrenceChief Financial OfficerBought
- Date
- 9 November 2026
- Shares
- 1,000
- Price
- $5.00
- Value
- $5,000
- Sherman DarrenSee Remarks, DirectorSoldunder a preset trading plan
- Date
- 2 November 2026
- Shares
- 15,000
- Price
- $5.74
- Value
- $86,100
- Sherman DarrenSee Remarks, DirectorSoldunder a preset trading plan
- Date
- 1 October 2026
- Shares
- 15,000
- Price
- $6.36
- Value
- $95,400
- Hochman David PSee Remarks, DirectorBought
- Date
- 3 September 2026
- Shares
- 10,000
- Price
- $4.79
- Value
- $47,900
- Sherman DarrenSee Remarks, DirectorSoldunder a preset trading plan
- Date
- 1 September 2026
- Shares
- 15,000
- Price
- $4.94
- Value
- $74,100
- Sherman DarrenSee Remarks, DirectorBought
- Date
- 26 August 2026
- Shares
- 2,000
- Price
- $5.33
- Value
- $10,660
- Sherman DarrenSee Remarks, DirectorSoldunder a preset trading plan
- Date
- 3 August 2026
- Shares
- 15,000
- Price
- $4.09
- Value
- $61,350
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 9 November 2026 | Fain Eric S Director | Bought | 20,000 | $5.00 | $100,000 |
| 9 November 2026 | Pacitti David Director | Bought | 20,000 | $5.00 | $100,000 |
| 9 November 2026 | Hochman David P See Remarks, Director | Bought | 5,000 | $5.00 | $25,000 |
| 9 November 2026 | Taylor Andrew Lawrence Chief Financial Officer | Bought | 1,000 | $5.00 | $5,000 |
| 2 November 2026 | Sherman Darren See Remarks, Director | Sold under a preset trading plan | 15,000 | $5.74 | $86,100 |
| 1 October 2026 | Sherman Darren See Remarks, Director | Sold under a preset trading plan | 15,000 | $6.36 | $95,400 |
| 3 September 2026 | Hochman David P See Remarks, Director | Bought | 10,000 | $4.79 | $47,900 |
| 1 September 2026 | Sherman Darren See Remarks, Director | Sold under a preset trading plan | 15,000 | $4.94 | $74,100 |
| 26 August 2026 | Sherman Darren See Remarks, Director | Bought | 2,000 | $5.33 | $10,660 |
| 3 August 2026 | Sherman Darren See Remarks, Director | Sold under a preset trading plan | 15,000 | $4.09 | $61,350 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
None of the warning signs we check for were found.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 12 Mar 2026, plus the 10-Q filed 10 Nov 2026 and 4 later 8-Ks.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Insiders have been buying together. The deep dive checks whether they know something the price doesn't.
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.